华中科技大学

Phase I Trial Establishes Maximum Tolerated Dose for Pegylated Liposomal Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma

- A phase I dose-escalation trial determined the maximum tolerated dose of pegylated liposomal doxorubicin (PLD) at 50 mg/m² when combined with ifosfamide for advanced soft tissue sarcoma treatment. - The combination demonstrated manageable toxicity with grade 3/4 hematological adverse events being most common, including leukopenia (86.96%) and neutropenia (82.61%). - Among 12 patients who continued treatment beyond dose-finding, the overall response rate reached 33.33% with a disease control rate of 83.33%. - The study showed no cardiotoxicity events, suggesting PLD offers a safer cardiac profile compared to conventional doxorubicin-based regimens.